IQVIA (NYSE:IQV) Price Target Cut to $232.00 by Analysts at JPMorgan Chase & Co.

IQVIA (NYSE:IQV - Free Report) had its price target cut by JPMorgan Chase & Co. from $240.00 to $232.00 in a research report released on Tuesday,Benzinga reports. They currently have an overweight rating on the medical research company's stock.

Other equities research analysts also recently issued research reports about the company. UBS Group decreased their price objective on IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a report on Friday, February 7th. Morgan Stanley upped their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Leerink Partners restated an "outperform" rating and issued a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. The Goldman Sachs Group reduced their price objective on IQVIA from $280.00 to $250.00 and set a "buy" rating for the company in a report on Friday, November 1st. Finally, Barclays cut their price objective on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $251.22.

IQVIA Trading Down 0.7 %

Shares of IQV traded down $1.33 during mid-day trading on Tuesday, reaching $192.68. 218,630 shares of the company were exchanged, compared to its average volume of 1,367,388. IQVIA has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market capitalization of $33.93 billion, a PE ratio of 25.69, a PEG ratio of 2.01 and a beta of 1.48. The business has a 50 day simple moving average of $199.73 and a two-hundred day simple moving average of $216.79.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, analysts predict that IQVIA will post 10.86 earnings per share for the current fiscal year.

Insider Activity

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of the business's stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now owns 1,275 shares in the company, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.60% of the company's stock.

Institutional Investors Weigh In On IQVIA

A number of large investors have recently made changes to their positions in the business. Norges Bank bought a new position in IQVIA in the 4th quarter worth $336,041,000. Raymond James Financial Inc. bought a new stake in IQVIA during the 4th quarter valued at approximately $236,120,000. American Century Companies Inc. boosted its position in IQVIA by 396.0% during the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock valued at $222,987,000 after acquiring an additional 905,960 shares in the last quarter. Invesco Ltd. raised its holdings in IQVIA by 53.4% in the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after purchasing an additional 902,226 shares in the last quarter. Finally, FMR LLC raised its holdings in IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock worth $684,213,000 after purchasing an additional 804,963 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.